Candel Therapeutics Under Investigation Following Major Stock Drop: What Investors Should Know

Candel Therapeutics Facing Investigation After Stock Plunge



In a troubling development for investors, Candel Therapeutics (NASDAQ: CADL) has seen over 26% of its stock value erased following the company's announcement on November 12, 2026. The firm disclosed that its Biologics License Application (BLA) submission for aglatimagene, intended for treating localized prostate cancer, has been postponed until mid-2027. This revelation comes as Candel prepared to raise $80 million from investors, partly to facilitate this critical BLA engagement.

Initially, the company had anticipated submitting the BLA in the fourth quarter of 2026. The updated timeline not only disappointed investors but has prompted an investigation concerning potential violations of securities laws related to this timeline adjustment. Candel's stock price reacted sharply to the announcement, dropping approximately $2.19 per share, heightening concerns regarding the disclosure of risks surrounding the BLA submission timeline.

Investors who purchased CADL shares and subsequently suffered losses due to this drop may be eligible to pursue compensation. Legal firm Levi & Korsinsky has initiated an investigation focused on whether Candel adequately disclosed the risks associated with the revised BLA submission schedule before the stock experienced its notable decline.

The implications of this investigation are considerable for those who invested in Candel. The investigation raises critical questions about Candel Therapeutics’ transparency concerning the anticipated BLA timeline and whether the company misled investors regarding the timing and approval process for aglatimagene.

In December 2024, Candel previously announced a public offering, which was intended to finance further development of its product candidates, including the BLA submission for CAN-2409—which is the same as aglatimagene. Candel's recent Form 10-Q also outlined the need for additional capital to commercialize aglatimagene. This last-minute disclosure was intertwined with a new $50 million equity program, which raises further suspicions amid the backdrop of timing discrepancies related to the BLA submission.

The investigation seeks to address whether Candel's public statements regarding the BLA submission were misleading. It also looks into whether the company failed to disclose the inherent risks involved in its submission timeline. Investors who acquired shares at inflated prices due to potentially misleading information might now have recourse.

Potential participants in the investigation need to document their losses and provide brokerage records showing purchase dates, share quantities, and prices paid for their CADL investments. Importantly, even those who have sold their shares at a loss might still qualify for participation based on when they purchased the shares, as losses incurred do not solely rely on current holdings.

Inquiries into this case highlight the importance of understanding securities law in the fast-evolving landscape of pharmaceutical investments and the responsibilities companies have in communicating transparently with their investors. The outcome of this investigation may set precedents regarding corporate accountability in health-related sectors.

For investors feeling the sting of this stock drop, resources are available to assist in evaluating their eligibility for financial recovery. Legal representatives, including those at Levi & Korsinsky, are prepared to review losses and guide affected investors on the next steps, ensuring they are informed and equipped to engage in potential recovery actions.

With Candel Therapeutics currently under scrutiny, the situation serves as a cautionary tale for investors to remain vigilant about the disclosures made by companies—especially those announcing critical timelines for regulatory approvals that can significantly impact stock performance.

Topics Financial Services & Investing)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.